Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Dexamethasone in Relapsed/Refractory MCL
NCT00786851Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jul 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Overall Response Rate at 3 years and Complete Response Rate at 3 years. Started Jul 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00786851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786851.